News Release

Asieris to Increase Presence at ASCO GU 2022

SAN FRANCISCO, February 16, 2022 – Asieris Pharmaceuticals (688176.SH), a global innovative biopharma company specializing in discovering and developing innovative drugs for the treatment of genitourinary tumors and other major diseases, will co-host an ASCO GU China Banquet at the 2022 ASCO Genitourinary Cancers Symposium (ASCO GU) on February 18. Dr. Neal Shore, Director of the Carolina Urologic Research Center, Chief Surgical Officer at Genesis Care US, as well as the clinical consultant and US principal investigator of Asieris, will attend and make a keynote speech.

Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He is the Chief Surgical Officer and Head of Urology at Genesis Care US. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina, USA.

Dr. Shore has conducted more than 350 clinical trials, focusing mainly on Genitourinary (GU) Oncology, and serves on the Boards of: Duke Global Health Institute, Society of Urologic Oncology, Bladder Cancer Advocacy Network, and is Immediate Past President of Large Urology Group Practice Association. He is a founder of both the CUSP Clinical Trials Consortium and DASHKO, a large urology practices data registry. He serves as the National Urology Research Director for Genesis Care US. He is the Co-Chair of the AUA International Prostate Cancer Forum and has served on the AUA Male Health and AUA Data Committees, the SITC Task Force for Prostate Cancer and Bladder Cancer, the Bladder Cancer Advocacy Think Tank, and the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE (Academic Editor), Urology Practice, World Journal of Urology, and serves as Editor of Everyday Urology-Oncology. He has more than 200 peer-reviewed publications and numerous book chapters; he performs peer review for Lancet Oncology, the New England Journal of Medicine, European Urology, Journal Urology, Urology, BJUI, PCPD, and numerous other high impact scientific journals.

A graduate of Duke University and Duke University Medical School, Dr. Shore completed a six-month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery & Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.

About this Event:

7:30-8:00 pm – Networking

8:00-8:05 pm – Welcome Remarks:

Dr. Melody Loyola, Director of Licensing & Business Development, American Society of Clinical Oncology (ASCO)

8:05-9:30 pm – Dinner

9:30-9:45 pm – Keynote Speech: “Global Clinical Trials and Cooperation Challenges”

Dr. Neal Shore, Director of Carolina Urologic Research Center; Chief Surgical Officer at Genesis Care US

 

About Asieris

Asieris Pharmaceuticals (688176.SH), founded in March 2010, is a global innovative pharma company specializing in new drugs for the treatment of genitourinary tumors and other major diseases. We strive to improve human health and help people live a more dignified life. We aim to become a global pharma leader that integrates R&D, manufacturing, and commercialization in our areas of focus, as we provide best-in-class integrated diagnosis and treatment solutions for patients in China and worldwide.

The company has been developing its proprietary R&D platform and core technologies, exploring new mechanisms of action, and efficiently screening and evaluating drug candidates. With a well-established in-house R&D system and expertise in global drug development, Asieris is committed to launching first-in-class drugs and other innovative products to address huge unmet needs in its areas of focus.

Asieris is also enhancing its pipeline for genitourinary diseases via proprietary R&D and strategic partnerships, while closely following cutting-edge technologies and therapeutics. The company strives to discover and identify unmet clinical needs, and adopts a forward-looking approach in product planning and life-cycle management. We aim to establish an outstanding portfolio that covers diagnosis and treatment in a bid to benefit more patients in China and globally.